Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Non-Current Assets (2020 - 2021)

Historic Other Non-Current Assets for SAB Biotherapeutics (SABS) over the last 2 years, with Q4 2021 value amounting to $13.1 million.

  • SAB Biotherapeutics' Other Non-Current Assets rose 547124.04% to $13.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $13.1 million, marking a year-over-year increase of 547124.04%. This contributed to the annual value of $13.1 million for FY2021, which is 547124.04% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Other Non-Current Assets of $13.1 million as of Q4 2021, which was up 547124.04% from $235111.0 recorded in Q4 2020.
  • SAB Biotherapeutics' Other Non-Current Assets' 5-year high stood at $13.1 million during Q4 2021, with a 5-year trough of $235111.0 in Q4 2020.